Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €87.58 EUR
Change Today +1.72 / 2.00%
Volume 53.0
S3F On Other Exchanges
S3F is not on other exchanges.
As of 10:30 AM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

santhera pharmaceuticals-reg (S3F) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/3/15 - €113.80
52 Week Low
04/22/14 - €2.78
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

santhera pharmaceuticals-reg (S3F) Related Businessweek News

No Related Businessweek News Found

santhera pharmaceuticals-reg (S3F) Details

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases in the areas of various orphan and niche indications in North America and the EU. The company offers Raxone/Catena for the treatment of Friedreich’s Ataxia. Its products under development include Raxone/Catena, which is in preparation for regulatory re-submission marketing authorization in Europe for Leber's Hereditary Optic Neuropathy, in a Phase III study for Duchenne Muscular Dystrophy, and in a Phase II study for Primary Progressive Multiple Sclerosis; omigapil that is in Phase I pharmacokinetics study in pediatric patients with Congenital Muscular Dystrophy; and Fipamezole, which has completed Phase IIb study for treatment of Dyskinesia in Parkinson's disease. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Liestal, Switzerland.

11.8 Employees
Last Reported Date: 04/7/14
Founded in 2004

santhera pharmaceuticals-reg (S3F) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: SFr.326.4K
Compensation as of Fiscal Year 2013.

santhera pharmaceuticals-reg (S3F) Key Developments

Santhera Pharmaceuticals Announces Phase III Trial with Raxone/Catena

Santhera Pharmaceuticals announced that Gunnar M. Buyse, PhD, MD, Professor of Child Neurology at the University Hospitals Leuven (Belgium), and principal investigator, will present outcome data of the Phase III trial with Raxone(R)/Catena(R) (idebenone) in Duchenne Muscular Dystrophy (DMD) at the upcoming annual meeting of the American Academy of Neurology (AAN).

Santhera Pharmaceuticals Announces Management Changes

Santhera Pharmaceuticals announced that announced the strengthening of the leadership team through nomination of senior members of staff to its Executive Management and the appointment of a Chief Commercial Officer. With effect of February 1, 2015, the Board of Directors announced the expansion of the company's leadership team and appointed senior staff members Nicholas Coppard, PhD, SVP Head Development, Gunther Metz, PhD, SVP Business Development, and Oliver Strub, General Counsel and Secretary to the Board, to the Executive Management Team headed by CEO Thomas Meier, PhD. Also effective February 1, 2015, Giovanni Stropoli has been appointed as Chief Commercial Officer for Europe and Rest of World. He will report to the company's CEO, Thomas Meier, and will also join the Executive Management. Mr. Stropoli joins Santhera from InterMune. Nicholas Coppard, PhD (SVP, Head Development) joined Santhera in 2008. Gunther Metz, PhD (SVP, Business Development) joined Santhera in 2004 from Graffinity, one of the two companies that merged to form Santhera. Previously he worked in drug discovery at Fournier Pharma. Oliver Strub (SVP, General Counsel & Secretary to the Board) joined Santhera in 2006. As an experienced commercial lawyer he previously worked as Head Corporate Law and Chief Compliance Officer for Ciba-Geigy and Ciba Specialty Chemicals (now part of BASF). Giovanni Stropoli (Chief Commercial Officer Europe & RoW) has over 25 years of experience in commercialization, sales and marketing of pharmaceutical products. Prior to InterMune, where he was responsible for the successful launch of the orphan drug Esbriet(R) in 11 countries, he held senior commercial functions with Eisai, ALK-Abello and Eli Lilly.

Santhera Pharmaceuticals Holding AG Presents at 17th Annual BIO CEO & Investor Conference, Feb-10-2015 11:00 AM

Santhera Pharmaceuticals Holding AG Presents at 17th Annual BIO CEO & Investor Conference, Feb-10-2015 11:00 AM. Venue: The Waldorf Astoria, New York, New York, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
S3F:GR €87.58 EUR +1.72

S3F Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for S3F.
View Industry Companies

Industry Analysis


Industry Average

Valuation S3F Industry Range
No financial data is available for S3F.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SANTHERA PHARMACEUTICALS-REG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at